Peptides are unusual among research compounds in that the route of administration matters a great deal for the experimental outcome. A peptide that produces a strong effect after subcutaneous injection in a rodent model may produce no effect at all after oral delivery in the same model. Researchers who work with peptides need a working understanding of the major delivery routes, the pharmacokinetic profiles each one produces, and the practical and stability considerations that determine which route is appropriate for a given experiment. This article surveys the main delivery routes used in preclinical peptide research. It is a companion to the broader comprehensive guide to peptides in research.
Why route matters for peptides
Peptides are not small molecule drugs. They are larger, more polar, and more susceptible to enzymatic degradation. A typical peptide cannot be made into a tablet and swallowed because the digestive enzymes of the gut would cleave it before it ever reached the circulation, and even an intact peptide would have a hard time crossing the intestinal epithelium because of its size and charge. The route of administration is therefore a fundamental design decision in any preclinical peptide experiment.
Different routes produce different pharmacokinetic profiles. The same total amount of peptide delivered by intravenous injection produces a sharp peak followed by rapid clearance. Delivered by subcutaneous injection, the same amount produces a slower rise to a lower peak followed by more sustained exposure. Delivered by intranasal spray, it produces a different profile shaped by absorption across the nasal mucosa. These differences matter for the experimental outcome and for the interpretation of the data.
The pharmacokinetic principles that govern peptide delivery in animal models are documented in the standard pharmacology literature. Journals indexed on the ScienceDirect topic page for peptide and the Wiley Online Library host primary research papers on the pharmacokinetics of specific peptides in rodent and other animal models.
Subcutaneous delivery
Subcutaneous injection is the most common route for systemic peptide research in animal models. The injection delivers the peptide into the loose connective tissue beneath the skin, where it diffuses into local capillaries and reaches the systemic circulation over a period of minutes to hours. The slow absorption profile of subcutaneous injection is often desirable in research because it produces a more sustained exposure than intravenous injection and because it is technically easier to perform than other parenteral routes in small animal models.
Subcutaneous bioavailability for most peptides is high but not always complete. Peptides delivered subcutaneously can be partially degraded at the injection site by local proteases, can be taken up by the lymphatic system rather than the blood capillaries, and can experience first pass metabolism in the lymph nodes for larger peptides. Despite these losses, subcutaneous bioavailability is generally above fifty percent and is often above seventy or eighty percent for well behaved peptides.
The peak plasma concentration after subcutaneous injection typically occurs at thirty minutes to a few hours after injection, depending on the peptide and the formulation. The slower onset and longer duration of exposure compared to intravenous injection makes the subcutaneous route the preferred choice for chronic dosing studies and for any experiment where steady exposure is more useful than a sharp peak. In Midwest Peptide product literature, peptides such as BPC-157, TB-500, GHK-Cu, and Tesamorelin have all been studied with subcutaneous delivery in published animal model research.
Intramuscular delivery
Intramuscular injection delivers the peptide into a skeletal muscle, where it is absorbed into the bloodstream through the dense capillary network of muscle tissue. Absorption is generally faster than subcutaneous because the blood flow through skeletal muscle is higher than the blood flow through subcutaneous tissue. Bioavailability is comparable to subcutaneous and is generally high.
Intramuscular injection is sometimes used in research models when local delivery to a tissue near the muscle is desired or when a slightly faster onset is needed. It is more invasive than subcutaneous injection and is technically more difficult in small rodent models, which is why subcutaneous injection is more common in basic preclinical research. In larger animal models such as rabbits, dogs, and primates, intramuscular injection is more practical.
Intravenous delivery
Intravenous injection delivers the peptide directly into the bloodstream and provides one hundred percent bioavailability by definition. The peptide is immediately distributed throughout the central blood compartment and then to peripheral tissues based on its physicochemical properties.
Intravenous injection is used in preclinical pharmacokinetic studies because it provides a clean reference for comparison with other routes. Bioavailability of any other route is typically calculated as the area under the concentration time curve after that route divided by the area under the curve after intravenous injection of the same dose. Intravenous injection is also used in research models where rapid onset is important, such as acute physiological experiments. The disadvantage is that the peak concentration after intravenous injection is much higher than after subcutaneous or intramuscular injection, which can produce different effects in some experiments and can also be technically demanding in small animal models.
Oral delivery
Oral delivery is generally a poor route for peptides. The digestive enzymes of the stomach and small intestine, including pepsin, trypsin, chymotrypsin, and a long list of others, cleave peptide bonds with high efficiency. Even peptides that survive enzymatic digestion still face the intestinal epithelium, which presents a tight barrier to molecules of peptide size and polarity. Oral bioavailability for most peptides is therefore very low, typically below one percent.
There are exceptions. Some peptides have unusual stability and can be absorbed in functional amounts after oral administration. BPC-157 is one example that has been studied with oral delivery in rodent research models, and the published literature describes effects after oral as well as subcutaneous administration. Cyclic peptides and peptides with extensive D amino acid substitution can also have improved oral stability compared to standard linear peptides.
There are also formulation strategies that can improve oral bioavailability. Enteric coatings can protect peptides from gastric acid. Permeation enhancers can transiently open intestinal tight junctions. Conjugation to absorption enhancing carriers such as bile acids or fatty acids can promote uptake. Peptide drug development has produced several oral peptide therapies in the last decade, demonstrating that the oral route is not closed to peptides as a class. Primary research literature on oral peptide delivery is available through the American Chemical Society publications portal and the Cell Press journal portal.
Intranasal delivery
Intranasal delivery uses the rich vasculature and the relatively large surface area of the nasal mucosa to absorb peptides into the systemic circulation. The nasal mucosa is more permeable than the intestinal epithelium and offers a non invasive alternative to injection for some peptide research applications.
Intranasal delivery is also of interest for direct nose to brain delivery. The olfactory nerve and the trigeminal nerve provide pathways from the nasal cavity to the central nervous system that bypass the blood brain barrier, and there is published research showing that some peptides can reach brain tissue via these pathways after intranasal administration. The nose to brain literature is large and includes work on peptides such as Selank and Semax, which have been studied with intranasal delivery in animal models of stress and learning.
The bioavailability of intranasal peptide delivery varies widely depending on the peptide and the formulation. Some peptides reach systemic concentrations comparable to subcutaneous injection, while others achieve much lower levels. Formulation with absorption enhancers can improve bioavailability but can also irritate the nasal mucosa, so there is a balance to strike.
Topical delivery
Topical delivery applies the peptide directly to the skin, usually for dermal research applications. The skin is a strong barrier to peptide absorption because of the stratum corneum, the outer layer of dead, lipid filled cells. Most peptides do not penetrate the stratum corneum well in their unmodified form. Formulation strategies including liposomes, microemulsions, and chemical permeation enhancers can improve skin penetration.
Topical delivery is most relevant for research peptides that act on local skin targets rather than systemic targets. GHK-Cu has been studied with topical delivery in animal models of wound healing and dermal repair, and the published literature describes effects on collagen synthesis, angiogenesis, and other dermal endpoints after topical application.
